Combined effects of suberoylanilide hydroxamic acid and cisplatin on radiation sensitivity and cancer cell invasion in non-small cell lung cancer

Molecular Cancer Therapeutics

Volumn 15, Issue 5, 2016, Pages 842-853

  Feng, Jianguo ^a   Zhang, Shirong ^b,c   Wu, Kan ^a,c   Wang, Bing ^a,c   Wong, Jeffrey Y C ^d   Jiang, Hong ^b   Xu, Rujun ^b   Ying, Lisha ^a   Huang, Haixiu ^b   Zheng, Xiaoliang ^e   Chen, Xufeng ^f   Ma, Shenglin ^b,c  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e INSTITUTE OF MATERIA MEDICA   (China)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; CISPLATIN; DNA; HISTONE H2AX; KU ANTIGEN; PROTEIN P53; RAD51 PROTEIN; VORINOSTAT; ANTINEOPLASTIC AGENT; HISTONE; HYDROXAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER STEM CELL; CARCINOGENICITY; CELL DIFFERENTIATION; CELL SURVIVAL; CLONOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA END JOINING REPAIR; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN VIVO STUDY; IONIZING RADIATION; LD50; MOLECULAR INTERACTION; MOUSE; MULTIMODALITY CANCER THERAPY; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIVITY; RADIOSENSITIZATION; TREATMENT DURATION; TUMOR GROWTH; TUMOR INVASION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL MOTION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; RADIATION TOLERANCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CISPLATIN; DISEASE MODELS, ANIMAL; DNA DAMAGE; DNA REPAIR; DRUG SYNERGISM; HISTONES; HUMANS; HYDROXAMIC ACIDS; LUNG NEOPLASMS; MICE; RADIATION TOLERANCE; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84969506840     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0445     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Yang P, Allen MS, Aubry MC,Wampfler JA,Marks RS, Edell ES, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005;128:452-62.
3. O'Rourke N, Roque IFM, Farre Bernado N, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2010:CD002140.
4. Jett JR, Schild SE, Keith RL, Kesler KA. Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:266S-76S.
5. Vokes EE, Senan S, Treat JA, Iscoe NA. PROCLAIM: a phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer 2009;10:193-8.
6. Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small cell lung cancer. J Clin Oncol 2010;28: 2181-90.
7. Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005;23:5883-91.
8. Koning CC, Wouterse SJ, Daams JG, Uitterhoeve LL, van den Heuvel MM, Belderbos JS. Toxicity of concurrent radiochemotherapy for locally advanced non-small cell lung cancer: a systematic review of the literature. Clin Lung Cancer 2013;14:481-7.
9. Le Chevalier T, Arriagada R,Quoix E, Ruffie P, Martin M, Douillard JY, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. Lung Cancer 1994;10Suppl 1: S239-44.
10. Blackstock AW, Govindan R. Definitive chemoradiation for the treatment of locally advanced non-small cell lung cancer. J Clin Oncol 2007;25: 4146-52.
11. Sears CR, Turchi JJ. Complex cisplatin-double strand break (DSB) lesions directly impair cellular non-homologous end-joining (NHEJ) independent of downstream damage response (DDR) pathways. J Biol Chem 2012;287:24263-72.
12. Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in amouse model of lung cancer. Genes Dev 2010;24:837-52.
13. Chen X, Wong JY, Wong P, Radany EH. Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis. Mol Cancer Res 2011;9:448-61.
14. Chen X,Wong P, Radany EH, Stark JM, Laulier C, Wong JY. Suberoylanilide hydroxamic acid as a radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma. Mol Cancer Res 2012;10:1052-64.
15. Bennardo N, Cheng A, Huang N, Stark JM. Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair. PLoS Genet 2008;4:e1000110.
16. Chen X, Radany EH, Wong P, Ma S, Wu K, Wang B, et al. Suberoylanilide hydroxamic acid induces hypersensitivity to radiation therapy in acute myelogenous leukemia cells expressing constitutively active FLT3 mutants. PLoS ONE 2013;8:e84515.
17. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
18. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-6.
19. Chan CH, Lee SW, Li CF, Wang J, Yang WL, Wu CY, et al. Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis. Nat Cell Biol 2010;12:457-67.
20. Yu C, Yao Z, Dai J, Zhang H, Escara-Wilke J, Zhang X, et al. ALDH activity indicates increased tumorigenic cells, but not cancer stem cells, in prostate cancer cell lines. In Vivo 2011;25:69-76.
21. Boeckman HJ, Trego KS, Turchi JJ. Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining. Mol Cancer Res 2005;3:277-85.
22. Mogi A, Kuwano H. TP53 mutations in non-small cell lung cancer. J Biomed Biotechnol 2011;2011:583929.
23. Allen C, Halbrook J, Nickoloff JA. Interactive competition between homologous recombination and non-homologous end joining. Mol Cancer Res 2003;1:913-20.
24. Jin KL, Park JY,NohEJ, Hoe KL, Lee JH, Kim JH, et al. The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells. J Gynecol Oncol 2010;21:262-8.
25. Banath JP, Klokov D, MacPhail SH, Banuelos CA, Olive PL. Residual gammaH2AX foci as an indication of lethal DNA lesions. BMC Cancer 2010;10:4.
26. Taneja N, Davis M, Choy JS, Beckett MA, Singh R, Kron SJ, et al. Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem 2004;279:2273-80.
27. MarchionD, Munster P. Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther 2007;7:583-98.
28. Karantzali E, Schulz H, Hummel O, Hubner N, Hatzopoulos A, Kretsovali A. Histone deacetylase inhibition accelerates the early events of stem cell differentiation: transcriptomic and epigenetic analysis. Genome Biol 2008; 9:R65.
29. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 2006;281:5612-22.
30. de Jong J, Looijenga LH. Stem cell marker OCT3/4 in tumor biology and germ cell tumor diagnostics: history and future. Crit Rev Oncog 2006;12: 171-203.
31. Carina V, Zito G, Pizzolanti G, Richiusa P, Criscimanna A, Rodolico V, et al. Multiple pluripotent stem cell markers in human anaplastic thyroid cancer: the putative upstream role of SOX2. Thyroid 2013;23:829-37.
32. Wang ML, Chiou SH,Wu CW. Targeting cancer stem cells: emerging role of Nanog transcription factor. OncoTargets Ther 2013;6:1207-20.
33. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. ProcNatl Acad SciU S A 2009;106: 16281-6.
34. Jaggupilli A, Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol 2012;2012:708036.
35. Chou SC, Azuma Y, Varia MA, Raleigh JA. Evidence that involucrin, a marker for differentiation, is oxygen regulated in human squamous cell carcinomas. Br J Cancer 2004;90:728-35.
36. Pfander D, Swoboda B, Kirsch T. Expression of early and late differentiation markers (proliferating cell nuclear antigen, syndecan-3, annexin VI, and alkaline phosphatase) by human osteoarthritic chondrocytes. Am J Pathol 2001;159:1777-83.
37. Chemotherapy for non-small cell lung cancer. CochraneDatabase Syst Rev 2000:CD002139.
38. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109:31-9.
39. Reguart N, Rosell R, Cardenal F, Cardona AF, Isla D, Palmero R, et al. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. Lung Cancer 2014;84:161-7.
40. Treatment of locally advanced non-small cell lung cancer (NSCLC). Updated: September 3, 2015. Available from: https://clinicaltrials. gov/ct2/show/NCT01059552.
41. Kong FM, Hayman JA, Griffith KA, Kalemkerian GP, Arenberg D, Lyons S, et al. Final toxicity results of a radiation-dose escalation study in patients with non-small cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys 2006;65:1075-86.
42. Socinski MA, Marks LB, Garst J, Sibley GS, Blackstock W, Turrisi A, et al. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium. Oncologist 2001;6Suppl 1:20-4.
43. Ward JF. The complexity of DNA damage: relevance to biological consequences. Int J Radiat Biol 1994;66:427-32.
44. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004;432: 316-23.
45. Dikomey E, Brammer I. Relationship between cellular radiosensitivity and non-repaired double-strand breaks studied for different growth states, dose rates and plating conditions in a normal human fibroblast line. Int J Radiat Biol 2000;76:773-81.
46. Borgmann K, DedeM,Wrona A, Brammer I,Overgaard J, Dikomey E. For X-irradiated normal human fibroblasts, only half of cell inactivation results from chromosomal damage. Int J Radiat Oncol Biol Phys 2004;58:445-52.
47. Kelley MR, Logsdon D, Fishel ML. Targeting DNA repair pathways for cancer treatment: what's new?Future Oncol 2014;10:1215-37.
48. Sampieri K, Fodde R. Cancer stem cells and metastasis. Semin Cancer Biol 2012;22:187-93.
49. Baccelli I, Trumpp A. The evolving concept of cancer and metastasis stem cells. J Cell Biol 2012;198:281-93.
50. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006;5:37-50.